DecisionDx-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients Unlikely to Benefit from Sentinel Lymph Node Biopsy

DecisionDx-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients Unlikely to Benefit from Sentinel Lymph Node Biopsy

New findings reveal DecisionDx-Melanoma more accurately identifies patients with under 5% risk of SLN positivity, supporting safer avoidance of SLNB surgery.

New Study Shows Castle Biosciences DecisionDx-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity

Patients identified as low risk by DecisionDx-Melanoma had a 2.8% sentinel lymph node (SLN) positivity rate, well below the National Comprehensive Cancer Network® (NCCN) guidelines’ 5% threshold to forgo sentinel lymph node biopsy (SLNB) surgery FRIENDSWOOD, Texas, April 30, 2025 (GLOBE NEWSWIRE) — Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests […]